With an unwavering focus on ‘Plasma Therapy for Life’, Intas is committed to delivering plasma products to ease the burden of care and improve the lives of patients with rare bleeding disorders and other ailments for which plasma-derived medicines are a safe and effective treatment. Our research strategy revolves around the objective of developing and delivering safe, effective, and affordable plasma products utilizing cutting-edge purification technology. Our innovation team believes in maximizing the value and performance of our existing therapies and developing new products to treat patients in need.

We intend to develop an ever-increasing product portfolio to cater to the unmet needs of the patients and increase their quality of life. The virus safety of all the products developed in our research and development facility is ensured at multiple stages of the process and validated in certified labs. In recent years, we have made major advances in the treatment of Hemophilia A and B, with the launch of our coagulation factors VIII & IX. Our normal immunoglobulin purification platform has enabled us to develop tailored Immunoglobulin products treating the outcome of primary and secondary immunodeficiency and other ailments and diseases for which these medicines are an effective treatment. Additionally, we are undertaking exciting research and development projects to develop treatments for new indications in Hematology, Hemostasis, and other important clinical areas.

As a result of our sharp focus on innovation, our scientists have pioneered the development of products not previously available in India, like the Subcutaneous Immunoglobulin (SCIg), Fibrinogen Concentrate, Prothrombin Complex, and C1 Esterase inhibitor. The development of Hyper Immune Globulin products supports our commitment to drug delivery in diverse areas of treatment ranging from critical care in COVID-19 to Prophylaxis and treatment in Hepatitis B, Erythroblastosis fetalis, and animal bite.